Fiche publication
Date publication
juillet 2020
Journal
Annals of the rheumatic diseases
Auteurs
Membres identifiés du Cancéropôle Est :
Pr JOUZEAU Jean-Yves
,
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Fauny M, Moulin D, D'Amico F, Netter P, Petitpain N, Arnone D, Jouzeau JY, Loeuille D, Peyrin-Biroulet L
Lien Pubmed
Résumé
Secukinumab, ixekizumab and brodalumab are monoclonal antibody therapies that inhibit interleukin (IL)-17 activity and are widely used for the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis. The promising efficacy results in dermatology and rheumatology prompted the evaluation of these drugs in Crohn's disease and ulcerative colitis, but the onset of paradoxical events (disease exacerbation after treatment with a theoretically curative drug) prevented their approval in patients with inflammatory bowel diseases (IBDs). To date, the pathophysiological mechanisms underlying these paradoxical effects are not well defined, and there are no clear guidelines for the management of patients with disease flare or new IBD onset after anti-IL-17 drug therapy. In this review, we summarise the literature on putative mechanisms, the clinical digestive effects after therapy with IL-17 inhibitors and provide guidance for the management of these paradoxical effects in clinical practice.
Mots clés
arthritis, psoriatic, biological therapy, spondylitis, ankylosing
Référence
Ann. Rheum. Dis.. 2020 Jul 21;:
